Stephen Furlong Sells 5,813 Shares of Neuronetics, Inc. (NASDAQ:STIM) Stock

Neuronetics, Inc. (NASDAQ:STIMGet Free Report) CFO Stephen Furlong sold 5,813 shares of the firm’s stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $3.39, for a total value of $19,706.07. Following the sale, the chief financial officer now directly owns 523,743 shares in the company, valued at $1,775,488.77. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Neuronetics Stock Up 0.3 %

NASDAQ:STIM opened at $3.60 on Friday. The company has a debt-to-equity ratio of 0.97, a current ratio of 4.63 and a quick ratio of 4.00. The business’s 50-day simple moving average is $2.86 and its two-hundred day simple moving average is $1.95. Neuronetics, Inc. has a 52 week low of $1.03 and a 52 week high of $6.15.

Neuronetics (NASDAQ:STIMGet Free Report) last posted its quarterly earnings results on Tuesday, November 7th. The company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.03). The business had revenue of $17.88 million for the quarter, compared to the consensus estimate of $17.66 million. Neuronetics had a negative net margin of 47.81% and a negative return on equity of 70.12%. On average, equities research analysts predict that Neuronetics, Inc. will post -1.13 EPS for the current year.

Institutional Investors Weigh In On Neuronetics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Cannell Capital LLC grew its position in shares of Neuronetics by 2.4% during the third quarter. Cannell Capital LLC now owns 2,833,982 shares of the company’s stock valued at $3,826,000 after purchasing an additional 65,240 shares in the last quarter. Kent Lake Capital LLC grew its position in shares of Neuronetics by 229.8% during the third quarter. Kent Lake Capital LLC now owns 2,329,287 shares of the company’s stock valued at $3,145,000 after purchasing an additional 1,622,938 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Neuronetics by 1.0% during the third quarter. Vanguard Group Inc. now owns 1,145,310 shares of the company’s stock valued at $3,642,000 after purchasing an additional 11,102 shares in the last quarter. Silvercrest Asset Management Group LLC grew its position in shares of Neuronetics by 16.4% during the second quarter. Silvercrest Asset Management Group LLC now owns 1,129,430 shares of the company’s stock valued at $2,428,000 after purchasing an additional 159,439 shares in the last quarter. Finally, Schroder Investment Management Group grew its position in shares of Neuronetics by 4.7% during the second quarter. Schroder Investment Management Group now owns 944,880 shares of the company’s stock valued at $2,031,000 after purchasing an additional 42,095 shares in the last quarter. 62.23% of the stock is owned by institutional investors.

Neuronetics Company Profile

(Get Free Report)

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.

Further Reading

Insider Buying and Selling by Quarter for Neuronetics (NASDAQ:STIM)

Receive News & Ratings for Neuronetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuronetics and related companies with MarketBeat.com's FREE daily email newsletter.